3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
57
Kidney Neoplasms
16
Neoplasms
15
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Carcinoma, Hepatocellular
8
Melanoma
7
Carcinoma
6
Glioblastoma
5
Clear-cell metastatic renal cell carcinoma
5
Lung Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Sarcoma
2
Pheochromocytoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraganglioma
2
Liver Neoplasms
2
Kidney Diseases
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
cT2a N0NxM0 Renal Tumor
1
Interventions
Sunitinib
3
avelumab
2
Nutrition Assessment
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Lysine Acetyltransferase 5
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Diseases
×
Axitinib
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts